
    
      The efficacy and safety of delafloxacin, compared to that of vancomycin plus aztreonam, will
      be evaluated in a population of patients with acute bacterial skin and soft tissue infections
      (ABSSSI), including major cutaneous abscesses, wound infections, cellulitis/erysipelas, and
      burn-related infections.
    
  